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The exact mechanisms that generate levodopa-induced dyskinesias (LID) during chronic lev-
odopa therapy for Parkinson’s disease (PD) are not yet fully established. The most widely
accepted theories incriminate the non-physiological synthesis, release and reuptake of
dopamine generated by exogenously administered levodopa in the striatum, and the aber-
rant plasticity in the cortico-striatal loops. However, normal motor performance requires
the correct recruitment of motor maps. This depends on a high level of synergy within
the primary motor cortex (M1) as well as between M1 and other cortical and subcortical
areas, for which dopamine is necessary.The plastic mechanisms within M1, which are cru-
cial for the maintenance of this synergy, are disrupted both during “OFF” and dyskinetic
states in PD. When tested without levodopa, dyskinetic patients show loss of treatment
benefits on long-term potentiation and long-term depression-like plasticity of the intracor-
tical circuits. When tested with the regular pulsatile levodopa doses, they show further
impairment of the M1 plasticity, such as inability to depotentiate an already facilitated
synapse and paradoxical facilitation in response to afferent input aimed at synaptic inhi-
bition. Dyskinetic patients have also severe impairment of the associative, sensorimotor
plasticity of M1 attributed to deficient cerebellar modulation of sensory afferents to M1.
Here, we review the anatomical and functional studies, including the recently described
bidirectional connections between the cerebellum and the basal ganglia that support a key
role of the cerebellum in the generation of LID.This model stipulates that aberrant neuronal
synchrony in PD with LID may propagate from the subthalamic nucleus to the cerebellum
and “lock” the cerebellar cortex in a hyperactive state. This could affect critical cerebellar
functions such as the dynamic and discrete modulation of M1 plasticity and the matching
of motor commands with sensory information from the environment during motor perfor-
mance. We propose that in dyskinesias, M1 neurons have lost the ability to depotentiate
an activated synapse when exposed to acute pulsatile, non-physiological, dopaminergic
surges and become abnormally receptive to unfiltered, aberrant, and non-salient afferent
inputs from the environment.The motor program selection in response to such non-salient
and behaviorally irrelevant afferent inputs would be abnormal and involuntary. The motor
responses are worsened by the lack of normal subcortico–cortical inputs from cerebellum
and basal ganglia, because of the aberrant plasticity at their own synapses. Artificial cere-
bellar stimulation might help re-establish the cerebellar and basal ganglia control over the
non-salient inputs to the motor areas during synaptic dopaminergic surges.
Keywords: levodopa-induced dyskinesias, dopamine, Parkinson’s disease, plasticity, motor cortex, cerebellum,
basal ganglia
INTRODUCTION
In spite of being the most efficacious drug for the relief
of motor symptoms of Parkinson’s disease (PD), l-3,4-
dihydroxyphenylalanine (also known as levodopa) almost invari-
ably generates disabling involuntary movements. Levodopa-
induced dyskinesias (LID) seldom occur with the first dose of
levodopa, but chronic exposure to the drug results in LID in 20–
30% of PD patients in ∼2 years and in 80% within 5 years (1).
The risk to develop LID is enhanced by younger age, longer dura-
tions of disease and levodopa treatment, greater disease severity
(1), higher levodopa dose (2), genetic etiology of the disease (3–
5) and genetic variability in the dopamine metabolizing enzymes
(6), dopamine receptor and transporter isoforms (7–9), and brain
derived neurotrophic factor (10).
Based on the timing of their appearance in a levodopa cycle,
LID are termed as “peak-dose dyskinesia” or “biphasic dyski-
nesia.” Peak-dose dyskinesias are associated with high plasma
concentrations of levodopa (11) and the maximum reduction in
Parkinsonian signs. Biphasic dyskinesias appear just before the
beginning and the end of the relief period of the Parkinsonian
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signs, disappear in the phase of maximum clinical response, and
occur below a critical, low level of plasma levodopa (12). Peak-dose
dyskinesias are often choreic and seldom pure dystonic move-
ments. Biphasic dyskinesias are stereotyped, repetitive, dystonic
movements that are usually confined to the legs, and may co-
occur with Parkinsonian signs elsewhere in the body. Dystonic
movements can also occur in patients not exposed to levodopa
and their presence correlates with akinesia of PD (13).
The neural mechanisms of LID, those that determine the clin-
ical type of LID (i.e., choreic or dystonic) and those allowing the
co-occurrence of Parkinsonism and biphasic dyskinesias, are still
not fully understood (13–16).
The most accepted models of LID implicate pre- and post-
synaptic changes at the cortico-striatal synapses and alterations
in the activity of dopaminergic and non-dopaminergic (e.g.,
glutamatergic) neurotransmitter systems. The degeneration of
dopaminergic neurons in the substantia nigra pars compacta
(SNc) is associated with a series of changes in the nigro-striatal
synapses such as a loss of tonic release of dopamine, diminished
dopamine storage, and reuptake capacity [for review see Ref. (17)].
Positron emission imaging studies have demonstrated abnormally
high levels of striatal dopamine 1-hour post-medication (18)
and reduced dopamine transporter (DAT) levels (19) in dyski-
netic patients. Brain concentrations of levodopa after peripheral
administration were also found to be higher in dyskinetic rats
than non-dyskinetic rats, though plasma levels were not different
(20), confirming this association. The availability of extracellu-
lar dopamine after exogenous levodopa administration depends
significantly on the serotoninergic neurons, which convert it to
dopamine and provide vesicular storage (21, 22). These neurons,
however, lack the DAT system and pre-synaptic dopamine D2
autoreceptors, which leads to unregulated release and reduced
clearance of dopamine (23). Denervation-dependent D1 receptor
super-sensitivity causing pronounced activation of the D1-bearing
striatal neurons (15) and changes in the dendritic and synaptic
morphology (24) are two other important post-synaptic determi-
nants of LID in animal models. Enhanced D1 receptor pathway
transmission in dyskinetic animal models can lead to hyperphos-
phorylation of key enzymes necessary for neural signaling in the
direct pathway (25). For example, GluR1, a subunit of AMPA
receptors, exhibits high phosphorylation levels of Ser831 and Ser845
in the membranes of medium spiny neurons (MSNs) after lev-
odopa treatment in dyskinetic rats (26). Thus, advanced PD is
a state characterized by the inability to maintain stable, physio-
logical, synaptic and extra-synaptic levels of dopamine, which in
turn favors aberrant pre- and post-synaptic plastic responses in
the striatum.
Here, we review the theories of LID related to striatal and corti-
cal maladaptive plasticity in PD in the light of (1) the recent studies
on motor cortex plasticity in different stages of evolution of PD
(27–31), (2) the current knowledge of the physiology and anatomy
of basal ganglia circuitry, including the reciprocal subcortical con-
nections between the basal ganglia and the cerebellum (32, 33),
and (3) the recent report of the role of cerebellar sensory process-
ing in the bidirectional modulation of primary motor cortex (M1)
plasticity (34) and the disturbance of this function in patients with
LID (30). We propose a model based on the plasticity changes in
PD that considers Parkinsonism, biphasic, and peak-dose dyskine-
sias as clinical manifestations of the abnormal interaction between
M1 and the interlinked subcortical structures including the basal
ganglia and cerebellum, during fluctuations in synaptic dopamine
levels.
BASAL GANGLIA CIRCUITRY
CORTICO–BASAL GANGLIO–THALAMO-CORTICAL LOOP
Based on current understanding, the cortico–basal ganglia–
cortical circuit functions as a complex, integrated network with
multiple feed-back and feed-forward loops (35). The motor cir-
cuitry that projects from motor cortical areas (primary motor
cortex, supplementary cortex, premotor cortex, and parts of the
somatosensory dorsal parietal cortex) has a somatotopic, gluta-
matergic relay with the GABA-ergic MSNs in the dorsolateral
portion of the post-commissural putamen and a small rim of the
head of the caudate (36). The MSNs are connected to the output
nuclei either indirectly, after relay in globus pallidus pars externa
(GPe) and subthalamic nucleus (STN), or directly. The globus
pallidus pars interna (GPi) and the substantia nigra pars reticu-
lata (SNr) are the output nuclei of the basal ganglia and project
to the premotor neurons in the ventral tier of thalamic nuclei
(i.e., ventro-anterior, VA and ventro-lateral, VL), the centrome-
dian (CM)/parafascicular (PF) complex, the pedunculo-pontine
nucleus, the superior colliculus, and the brain stem (37–39). The
VA/VL thalamic nuclei project to the supplementary motor area
(SMA) and, to a lesser extent, to M1 and premotor cortex (38).
In addition to the afferent input from putaminal MSNs and GPe
neurons to STN, a hyper-direct glutamatergic pathway relays input
from M1, SMA proper and pre-SMA, and dorsal and ventral
premotor cortices to the dorsal aspect of STN (40–42). These
hyper-direct glutamatergic cortico–STN connections, along with
the STN–GPe and GPe–GPi connections, constitute the cortico–
STN–pallidal pathways that bypass the striatum. The STN also
receives glutamatergic projections from the thalamic PF and CM
nuclei (43, 44). There are direct projections from STN to the cor-
tex (45, 46) and to the thalamus (47). There are also dopaminergic
projections from the SNc to STN (48, 49). Thus, dopamine can
be seen to influence all glutamatergic synapses within the basal
ganglia–thalamo-cortical circuit (Figure 1).
RECIPROCAL BASAL GANGLIO–CEREBELLAR CIRCUITRY
A major recent advance has been the identification of topograph-
ically organized, reciprocal links between basal ganglia and the
cerebellum in non-human primates. Retrograde viral transporter
studies in primates showed direct projection from the dentate
nucleus, a major output of cerebellum, to the CM/PF complex
intralaminar nuclei in the thalamus and subsequently to the dor-
solateral putamen (32, 50). This bisynaptic path extends with a
third synapse from putamen to GPe (32). It was recently shown
in primates that the STN projects not only to the GPi, but also
has topographically organized projections to lobule VII B and
Crus II in the cerebellum via the pontine nuclei (51). The iden-
tification of bilateral subcortical communications between basal
ganglia and cerebellum, besides their convergence to partially over-
lapping cortical areas (52–54), makes it imperative to examine the
interaction between the abnormal basal ganglia activity and the
Frontiers in Neurology | Movement Disorders August 2014 | Volume 5 | Article 157 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kishore and Popa Cerebellum and levodopa-induced dyskinesias in PD
cerebellar circuits in PD that could contribute to the development
of Parkinsonism or LID.
DOPAMINERGIC SIGNALING IN THE MOTOR CIRCUITS IN
HEALTH
DOPAMINE AND BASAL GANGLIA
Dopaminergic fibers from the SNc innervate the striatum and all
structures in the basal ganglia, including the STN and GPi, as
well as the prefrontal, motor, and sensory cortices (55). Striatal
synaptic and extra-synaptic dopamine levels are maintained at
a constant level (56), independent of SNc neuronal firing, due
to the efficient dopamine reuptake by the DAT system in the
striatum (57) and the auto-inhibition mediated by presynaptic
dopamine D2 receptor stimulation (58). The cortex and thala-
mus send massive glutamatergic input to the GABA-ergic striatal
MSNs (59, 60) and dopamine has a pre-synaptic modulatory effect
on this excitation (61). Post-synaptically, dopamine also stabi-
lizes the firing rate and excitability of striatal neurons, inhibiting
D2-bearing neurons and facilitating D1-bearing striato-pallidal
neurons (62). Dopamine also regulates plasticity of striatal neu-
rons by modulating glutamate-mediated long-term potentiation
(LTP), long-term depression (LTD), and depotentiation (which
is a homeostatic mechanism of reversal of a potentiated synapse
to its pre-potentiated state) at the cortico-striatal synapses (63).
Striatal LTP and LTD are important for motor learning, while
depotentiation is thought to be necessary for removing unneces-
sary motor information (64). The activation of D1 receptors is
necessary for induction of both LTP and depotentiation, while the
co-activation of D1 and D2 receptors is required for induction
of LTD. Thus, the midbrain dopaminergic neurons [SNc–ventral
tegmental area (VTA)], through their projections to multiple basal
ganglia nodes that receive glutamatergic inputs, can influence
the local neural transmission as well as the induction of plas-
ticity at these nodes (Figure 1). Dopamine can also indirectly
influence M1 plasticity by regulating the basal ganglia inputs
reaching M1.
DOPAMINE AND PRIMARY MOTOR CORTEX
Neuroanatomical studies have confirmed the presence of direct
dopaminergic innervations from the midbrain to M1 in rats (65,
66), monkeys (67), and human beings (68), as well as the presence
of dopamine D1 and D2 receptors in M1 (69–72). A recent study,
using the more specific DAT immunostaining method in mice,
confirmed direct dopaminergic innervations of deep layers of M1
(73). D2 receptor agonists that increased the firing rate of pyrami-
dal neurons proved the effect of dopamine on M1 neurons. This
effect could be either due to a direct increase of pyramidal neuronal
excitability or due to a reduction of inhibitory interneuronal activ-
ity (74). An important role of dopamine in M1 is to facilitate motor
learning (66, 75) and motor memory encoding (76). In rats, the
impaired LTP and motor skills learning following dopaminergic
deafferentation of M1 could be corrected by local administration
of levodopa within M1 using osmotic mini-pumps (66). However,
denervation of SNc resulted in a total loss of motor skills learning,
far more severe than direct M1 denervation (77). Vitrac et al. (73)
showed that D1 receptors can enhance the associability of the pre-
and post-synaptic activity: by increasing the sensitivity and the
time-window for LTP induction, they serve as “coincidence mod-
ulators” that can determine whether a synapse will undergo LTP in
response to a set of activity patterns. Dopamine is also considered
necessary for the stability of motor representations within M1,
as local injection of D2 receptor blockers results in the collapse
of motor representations and of motor cortex excitability (78).
This may be because both D1 and D2 receptor-mediated mech-
anisms within M1 are necessary for the intracortical horizontal
connections to form LTP (75).
In human beings, studies in which plastic changes in M1 were
artificially induced with non-invasive stimulation techniques (e.g.,
transcranial direct current stimulation, tDCS, and transcranial
magnetic stimulation, TMS) revealed that dopamine has a non-
linear dose-dependent effect on M1 plasticity (79–81), which is
mediated through both D1 and D2 receptor subtypes (82). In
healthy subjects, both low and excessive exogenous dopamine
impair both facilitatory and inhibitory cortical plasticity (80,
83), while medium doses of oral levodopa have more stable
effects and can even enhance performance in motor learning
tasks (76).
DOPAMINE AND CEREBELLUM
Animal studies revealed that there is a small but well-defined
dopaminergic system in the cerebellum, which expresses all types
of dopamine receptors and whose properties are similar to the
striatal dopaminergic system (84). It receives inputs from the SNc
and VTA that terminate in the granule and Purkinje cell layers
(85–88). This system is important for the optimal development
and functioning of both the cerebellum and the basal ganglia. Loss
of nigral neurons in neonatal 6-OHDA-treated rats affects post-
natal cerebellar development (89) and the expression of GABAA
receptor subtype (90). This highlights the dependency of cerebel-
lar development on dopaminergic input, which could be direct or
indirect through the basal ganglia. In addition, both the degener-
ation of Purkinje cells in a knock-out rat model (84) and kainic
acid-induced degeneration of cerebellar cortex with preservation
of deep cerebellar nuclei (91) led to up-regulation of D1 receptors
and DAT in the striatum. This suggests that the cerebellar cortex,
through the deep nuclei and the thalamic relay, down-regulates
the striatal D1 receptors.
Besides the modulation of the striatal dopaminergic system, the
cerebellum also regulates the cortical dopaminergic system, since
electrical stimulation of dentate nucleus can induce dopamine
release within the prefrontal cortex in mice (92). This might
occur either through dentato-tegmental projections or through
dentato-thalamo-cortical projections (93).
In healthy humans, fMRI studies have shown strong connec-
tivity between SNc and cerebellum (94, 95). This connectivity
between SNc and cerebellum is lost in PD but is restored by
levodopa (96). Thus dopamine has both a direct and indirect
influence on the cerebellum.
DOPAMINERGIC SIGNALING IN PARKINSONISM AND
LEVODOPA-INDUCED DYSKINESIA
STRIATAL SIGNALING
According to the current models of basal ganglia in PD, dopamine
depletion causes under-activation of GPe and disinhibition of STN
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FIGURE 1 | Schematic representation of the basal ganglia-
thalamo-cortical loop, the cerebello-thalamo-cortical loop and the
interaction between the two in health (A), in non-dyskinetic
Parkinson’s disease, after levodopa withdrawal (OFF) and after regular
dose of levodopa (ON) (B), and in advanced Parkinson’s disease with
levodopa-induced dyskinesia (C). Red arrows represent glutamatergic
projections; blue arrows represent GABA-ergic projections; green arrows
represent dopaminergic projections; dark green arrows in panel B and C
represent the exogenous dopamine from levodopa. The shades of the
blocks represent the activity of the respective network nodes. The STN is
overactive because of cortical glutamatergic over activity during dyskinesias
and from loss of GPe inhibition in OFF. The STN over activity locks cerebellar
cortex in a persistent hyperactive state and interferes with its sensory
processing function. The behavior of the cortico-ponto-cerebellar projections
in non-dyskinetic PD in ON is not reported so far and is predicted by this
model to be close to normal (CB ctx, cerebellar cortex; CM, centromedian
thalamic nucleus; D1/D2, dopamine receptor types of the striatal medium
spiny neurons (MSNs); DN, dentate nucleus; GPe, globus pallidus externus;
GPi, globus pallidus internus; M1, primary motor cortex; PF, parafascicular
nucleus; PMC, premotor cortex; PN, pontine nuclei; SMA, supplementary
motor area; SNc, substantia nigra, pars compacta; SNr, substantia nigra,
pars reticulata; STN, subthalamic nucleus; VL, ventro-lateral thalamic
nucleus; VLPo, ventro-latero-posterior thalamic nucleus, pars oralis; VTA,
ventral tegmental area).
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in the indirect pathway (Figure 1B). STN over-activity in PD could
not only be due to abnormalities of the indirect pathway, but also
to the direct excitatory drive from the motor cortex and thalamus
(97, 98). This could lead to excessive activation of GPi, a dysfunc-
tion favored also by the reduced input from D1 pathway. The net
outcome would be enhanced GABA-ergic inhibition of thalamic
projections to motor areas. It is now considered that not only firing
rates but also firing patterns are important in maintaining normal
signaling within the motor circuit. Intra-operative recordings in
PD patients have demonstrated oscillations of local field poten-
tials in the beta band in the STN that are synchronized with beta
band oscillations in the cerebral cortex and GPi, indicating that
excessive synchronization is a feature of the whole basal ganglia–
cortical network. Dopaminergic drugs (99, 100) and STN DBS
(101) can suppress the abnormal synchrony between basal gan-
glia and cortex. Moreover, suppression of beta band synchrony
by these interventions positively correlates with improvement in
bradykinesia and rigidity.
Levodopa treatment, however, does not restore basal ganglia
activity to normal and LIDs are associated with reduced activity
in the STN and GPi neurons. For example, peak oscillations at
4–10 Hz associated with dyskinesia were recorded only from the
contralateral STN in patients with asymmetrical LID (102). Such
abnormal oscillations in Parkinsonian and dyskinetic states could
potentially propagate from the STN to the cerebellum in PD.
STRIATAL PLASTICITY IN PARKINSONISM AND LID
In animal studies, striatal LTP and LTD are both impaired if
dopaminergic afferents to striatum are lesioned but can be restored
by levodopa (103). In human beings, the direct evidence of
dopaminergic influence on an extrastriatal site was demonstrated
in SNr neuronal plasticity during DBS surgery; local field poten-
tial amplitude of SNr neurons showed no enhancement after high
frequency stimulation of STN when tested without levodopa,
but enhancement was evident following the administration of
levodopa (104).
In the rat models of PD and LID, striatal LTP was impaired in
both non-dyskinetic and dyskinetic rats and could be restored by
levodopa in both groups (64). In contrast, the capacity to depo-
tentiate LTP was preserved only in non-dyskinetic rats. In the rat
model, both the presence of dyskinesias and the loss of depoten-
tiation were linked to higher doses of levodopa (105). This shows
that loss of depotentiation at the cortico-striatal synapses from
levodopa exposure is a marker of LID in animal models.
CORTICAL SIGNALING
A significant loss of dopamine and noradrenaline occurs in the
motor cortex of PD patients (36, 55, 68). This postmortem find-
ing was confirmed in vivo by PET of the motor cortex (106), motor
cortical pathology was therefore proposed to underlie some of the
symptoms of PD (106, 107). In line with this hypothesis, anti-
PD drugs can modulate the activity of motor cortex (108) and
non-invasive stimulation of the motor cortex can help reduce
symptoms of PD and LID by reestablishing the homeostasis of
some circuits (109). However, the kinetics of cortical dopamine
within M1 is yet to be explored in human beings and animal
models of LID.
MOTOR CORTEX PLASTICITY
In human PD, changes in motor cortex plasticity have been studied
using transcranial magnetic stimulation (TMS), delivered alone as
theta-burst (TBS) or as a paired associative stimulation (PAS), in
which magnetic pulses delivered over M1 are classically associated
with sensory pulses delivered on a peripheral nerve (Figure 2).
The plastic effects of TBS depend on the stimulation pattern,
which will act upon the intracortical synapses within M1. The
sensorimotor plastic effects of PAS depend on the coincidence of
pre- and post-synaptic neuronal activation within a specific time
window (110–112). Using TBS in de novo PD, the LTP- and LTD-
like plasticity of the intracortical circuits within M1was shown to
be symmetrically and severely impaired even though the motor
symptoms were unilateral (29). There was also no correlation of
the plasticity loss with motor signs of PD, indicating that that M1
changes were more likely the direct consequence of mesocortical
denervation than the indirect consequence of striatal denerva-
tion, the latter being more correlated with Parkinsonian signs. It
also indicates that changes in M1 plasticity occur at a lower level
of dopaminergic denervation than the higher threshold of 60–
80% striatal dopaminergic denervation necessary for the motor
signs to develop. Additionally, the local M1 plasticity in de novo
patients did not show any short-duration response to a single
dose of 100 mg levodopa, while clinical deficits showed signifi-
cant improvement. This indicated that normalization of plastic
mechanisms within M1 needs sustained dopamine replenishment.
It was subsequently demonstrated that the propensity of intra-
cortical circuits in the motor cortex to express normal plastic
responses was closely linked to the stability of clinical response
to levodopa (28):
(1) Patients with stable clinical response to levodopa with no fluc-
tuations in their clinical response to levodopa and without
LID could express LTP and LTD even when tested without
levodopa. This suggests a beneficial and persistent treatment
effect of levodopa therapy on M1 plasticity when compared
to the severe loss of plasticity in the untreated state.
(2) Patients with wearing-off motor fluctuation showed a persis-
tent treatment effect of chronic levodopa treatment on LTP,
but not on LTD. In these patients, exposure to an acute boost
of dopamine, by administering their regular dose of levodopa,
revealed a detrimental effect of dopamine on both LTP and
LTD.
(3) Patients with both motor fluctuations and dyskinesias have no
persistent treatment effect on either LTP or LTD. Acute boost
of levodopa did not restore LTP or LTD. Interestingly, acute
dopamine boost led to a paradoxical LTP in the motor cortex
of these patients in response to an intervention that normally
induces LTD in healthy subjects. The paradoxical facilitation
was more in those with more severe disease and with higher
clinical response to levodopa, suggesting that both are con-
sequences of the acute dopamine replacement. Moreover, PD
patients with LID are unable to depotentiate an already estab-
lished LTP in M1after an acute dosing with even a small dose
of levodopa (113). This finding is similar to changes in the
striatum of dyskinetic animals (64), but in contrast to non-
dyskinetic patients in whom depotentiation was present after
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FIGURE 2 | Schematic overview of the evolution of plasticity in Parkinson’s disease from the stable, non-dyskinetic state to the dyskinetic state.
their regular dose of levodopa. PD patients with LID could
express LTP in M1, but only when given half the regular dose
of levodopa, reconfirming the negative effect of the regular
dose on LTP. All these findings point to a severe dysregula-
tion of intrinsic plastic mechanisms within M1 of patients
with LID.
Additionally, studies using PAS have also revealed severe loss
of sensorimotor, associative plasticity of M1 in the more affected
hemisphere of denovo PD patients (31). Unlike the plastic response
of the local intracortical circuits, the impairment in associative
plasticity in the more affected hemisphere correlated with the
severity of motor signs of PD, indicative of a dependence on stri-
atal denervation underlying both. The short-duration response of
associative plasticity to levodopa in de novo patients has not been
studied so far. However, associative plasticity of M1can be restored
by dopaminergic drugs only in chronically treated patients that are
non-dyskinetic and not in dyskinetic ones (27).
Besides the plastic responses, intracortical inhibitory circuits
are also altered in M1 of treated PD patients. GABAA-mediated,
short-interval intracortical inhibition is reduced in PD patients,
both dyskinetic and non-dyskinetic, when compared to controls,
and levodopa could not correct this (114). In the same study,
long interval intracortical inhibition was weaker than in con-
trols in both non-dyskinetic and dyskinetic patients tested without
levodopa, but levodopa could weakly correct this in dyskinetic
patients. The lack of positive effect of levodopa on intracortical
inhibition in M1 and the negative effect of levodopa on short
latency afferent inhibition (115) has also been suspected to play a
role in LID.
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CEREBELLAR LINK TO MOTOR CIRCUITS IN HEALTH,
PARKINSONISM AND LID
CEREBELLAR PLASTICITY IN HEALTH
Within the motor control loops, the cerebellum controls and
co-ordinates complex movements and is important for adapt-
ing movements to changes in feed-back. It receives sensory and
motor information from descending cortical pathways and from
ascending peripheral pathways. It has also connections to the
parietal, premotor, and frontal cortices. The two major excita-
tory afferents to cerebellum are the climbing fibers and mossy
fiber – parallel fiber systems, information from both of which
eventually converges on the Purkinje cells that represent the only
efferent output from the cerebellar cortex. The exteroceptive and
proprioceptive inputs from the spinal cord and the input from
pontine nuclei convey information from brainstem nuclei via
mossy fibers to the granule cells. The axons of granule cells form
the parallel fibers network. Climbing fibers originate in the infe-
rior olive and relay directly to the Purkinje cells. Plastic changes
in the strength of synapses relaying from the climbing and par-
allel fibers to the Purkinje cells are important in motor learning.
Plasticity of climbing fibers input bi-directionally adjusts the plas-
ticity of parallel fibers–Purkinje cells synapses. This suggests a
role of climbing fibers as an error detector, which signals the
need for adjusting the gain of sensory inputs and/or motor out-
put within the cerebellum. Any disturbance in cerebellar plastic-
ity could interfere with this function and result in maladjusted
information delivered to M1, leading to abnormal, movement
sequences.
CEREBELLAR PLASTICITY DYSFUNCTION IN PARKINSON’S DISEASE
AND LID
There are several lines of evidence suggesting that cerebello–
thalamo-cortical communication is abnormal in PD. In animal
models of PD, the thalamic neurons that receive cerebellar output
are underactive, just as those receiving basal ganglia afferents
(116), indicative of a reduced dentato-thalamo-cortical excita-
tory output. In the MPTP mouse model, nigral degeneration is
accompanied by loss of Purkinje cells in the cerebellum (117).
In the untreated chronic MPTP monkey model of PD, nigral
degeneration correlates with persistent hyperactivity in the cere-
bellum (118). Such a hyperactive state, secondary to striatal
dopaminergic denervation, could prevent the efficient process-
ing of the inputs from both parallel and climbing fibers, thus
interfering with the plasticity mechanisms within the cerebellar
cortex. One potential source of cerebellar hyperactivity could be
the pathological hyperactivity in the glutamatergic projections
from STN to cerebellum (Figures 1B,C). There is now increas-
ing clinical, electrophysiological, and functional imaging evidence
to invoke a cerebellar dysfunction in PD – for review see Ref.
(119).
In the monkey model of PD, the ventro-lateral posterior nucleus
of the thalamus that receives cerebellar output shows oscillations
at tremor frequency, while in human PD, cerebellum has been
linked to the postural tremor (120, 121). Also in PD patients,
tremor-related abnormal oscillatory activity was recorded in the
STN and GPi but not in the thalamic nuclei receiving basal gan-
glia input (122, 123). Considering the newly described anatomical
connections between the basal ganglia and the cerebellum, it
is conceivable that abnormal oscillations from a cerebellar cir-
cuit could propagate either to M1 and subsequently to STN via
hyper-direct pathway, or from cerebellum to striatal MSNs pro-
jecting to GPe–STN via the indirect pathway. Defects in striatal
dopamine release (124) and in cerebellar sensory processing func-
tion (125) were recently found in patients with primary focal dys-
tonia. Abnormal signaling between basal ganglia and cerebellum
in human PD could therefore potentially cause dystonic symptoms
in untreated PD and during low plasma levels of dopamine as in
biphasic dyskinesias.
Despite the classical view that LID might be generated exclu-
sively by the disinhibition of cortical motor areas secondary to
abnormal output from the basal ganglia in the striato–thalamo-
cortical circuit (17), there is indirect evidence that the cerebellum
may play a role in it.
In patients with PD, the binding potential of sigma receptors
in the cerebellum (as explored with PET) is highly increased with
respect to healthy controls and correlates only with LID scores
and not with severity scores of Parkinsonian signs (126). Sigma
receptor stimulation influences Purkinje cell firing (127) and
also plays a role in the modulation of the glutamatergic/NMDA
neurotransmission in the dopaminergic systems (128). Success-
ful stereotaxic pallidal surgery (either pallidotomy or deep-brain
stimulation) can lower this exaggerated sigma receptor binding in
the cerebellum in LID (126).
Further evidence of cerebellar involvement in LID comes from
TMS studies. In patients with PD, with mild to moderate LID,
repeated sessions of bilateral cerebellar inhibitory stimulation
after regular doses of levodopa induce a sustained reduction of
dyskinesia lasting at least 2 weeks (30, 129). Repeated cerebel-
lar stimulation can also reduce the cerebellar cortical activity
and enhance dentate nuclear activity in imaging studies in PD
patients with dyskinesias (130). In such patients, a single session
of inhibitory stimulation of the cerebellar cortex combined with
levodopa can restore the sensorimotor plasticity tested by PAS,
but not the local intracortical plasticity as tested with TBS (30).
This effect of cerebellar stimulation would have improved M1
plasticity induced by both PAS and TBS, if cerebellar stimula-
tion was modifying directly M1 excitability. The lack of effects
of cerebellar stimulation on intracortical plasticity of M1 and on
intrinsic cortical excitability parameters (as reflected by the motor
thresholds or intracortical facilitation and inhibition) supports
a primarily subcortical mechanism. Recent studies showed that
cerebellar stimulation can modulate the M1 associative heterosy-
naptic plasticity in healthy subjects (131) through the modula-
tion of peripheral sensory afferents (34), eventually scaling the
amplitude and topographic specificity of the associative plastic
response (34); excitation of the posterior cerebellar cortex led to
loss of associative plastic response, while inhibition of the cere-
bellar cortex led to prolonged facilitatory response to PAS with
loss of topographic specificity. These were observed for PAS but
not for TBS, suggesting that the target of cerebellar modula-
tion is mainly the afferent input to M1 rather than M1 in itself.
Cerebellar cortical excitation (i.e., heightened output of the Purk-
inje cells) leads to the enhancement of the normal inhibition of
the dentate nucleus, which would reduce the normal excitatory
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control of dentate nucleus on the afferent inflow to M1, prob-
ably at the thalamic or olivary nuclear level, thus blocking the
sensorimotor-plasticity within M1. In contrast, cerebellar corti-
cal inhibition (i.e., depressed output of the Purkinje cells) could
lead to disinhibition of dentate nucleus, which would facilitate
afferent input to M1 (34). This model is in keeping with the adap-
tive filtering role of the cerebellum on sensory afferents (132).
Additionally, repeated sessions of inhibitory stimulation of the
posterior cerebellar cortex can restore the levodopa-unresponsive,
associative M1 plasticity in dyskinetic PD patients, concurrent
with the reduction in LID severity (30). Several findings of this
particular study suggested that the reduction in LID could be
related to the improvement of responsiveness of M1 to PAS after
cerebellar inhibition: (1) larger facilitation of M1 plasticity after a
single session of cerebellar inhibitory stimulation in ON predicted
greater anti-dyskinetic effect of repeated cerebellar stimulation in
the same subjects; (2) the time course of LID improvement was
similar to the time-course of the associative plasticity restoration
after 10 consecutive sessions of cerebellar stimulation; and (3)
patients with more severe LID before the TMS treatment showed
larger responsiveness of M1 to cerebellar inhibition suggesting
more involvement of the cerebellum in the pathophysiology of
dyskinesias as the severity of LID increases. However, cerebellar
stimulation did not worsen or enhance the Parkinsonian signs
in OFF or beyond the effect of levodopa alone. Patient diaries
revealed that the time spent in ON without troublesome dyski-
nesias, but not the durations of the OFF periods, was improved
by cerebellar stimulation. These suggest that combined levodopa
replacement therapy and cerebellar inhibition might be required
to restore the balance between the two circuits and to concurrently
improve Parkinsonian signs and reduce dyskinesias. Exogenously
derived dopamine might act by increasing the excitability of M1
neurons (73) and normalizing basal ganglia signaling, whereas
inhibition of the cerebellar cortex enhances the gain of the sen-
sory afferent input and allow better sensorimotor integration (34).
It remains speculative whether cerebellar hyperexcitation exists in
de novo human PD as in de novo animal model of PD and if
this cerebellar defect contributes to the genesis of specific man-
ifestations like tremor or dyskinesias. If it were the case, then
this metaplastic state of the cerebellar cortex could be reversed or
delayed by early artificial inhibitory stimulation of the cerebellar
cortex.
Earlier neuroimaging studies have found increased activity
of motor and premotor areas in dyskinetic PD patients when
compared to non-dyskinetic patients (133, 134). This led to the
classical view that hyperactivity in cortical motor areas might be
responsible for LID (17, 135). However, inhibitory stimulation
of SMA (135, 136) or of M1 (137) failed to provide sustained
improvement of dyskinesias. The results obtained recently with
cerebellar stimulation point to an alternative explanation, which
reconciles with the observations in these older studies: as SMA,
pre-motor cortex, and M1 are all targets of cerebellar output (54).
An abnormal input from the cerebellum to SMA or M1 in dysk-
inetic patients might indeed trigger abnormal fMRI activations,
but only as downstream, secondary, phenomena, thus making
them unsuitable targets for a direct intervention for the treatment
of LID.
PROPOSED MODEL OF PARKINSONISM AND
LEVODOPA-INDUCED DYSKINESIA BASED ON ABERRANT
PLASTICITY
This model is based on the view that a physiological level
of dopaminergic stimulation is critical for maintaining normal
plasticity at the glutamatergic terminals in the interconnected
large motor network involving the basal ganglia, motor cortices,
thalamus, and sensorimotor areas of the cerebellum. This model
considers M1 only as the final target of this network and pro-
poses LID as the product of a cascade of changes triggered by
the altered dopaminergic signaling in this network. M1 neurons
deprived of the ability to depotentiate activated synapses due to
abnormally high synaptic dopamine levels during peak-dose, are
rendered indiscriminately receptive to non-salient or even aber-
rant afferent inputs from the environment conveyed by other
neural structures (spino-thalamic pathways via ventro-lateral thal-
amic nuclei, other cortical areas via direct cortico-cortical con-
nections, etc.). This defect may be additionally amplified by the
aberrant signals reaching M1 from the thalamic relays errati-
cally modulated by the basal ganglia and cerebellum (Figure 1C).
The result would be the inappropriate selection of motor pro-
grams and the generation of movements that are both unwanted
and abnormal. The absence of effective inhibitory control within
M1 and the paradoxical facilitation during attempted inhibition
would make these movements resistant to voluntary suppression
and even exacerbate them. Biphasic dyskinesia co-existing with
Parkinsonism may reflect transitory oscillations in the synaptic
dopamine levels during the rising and falling phases of release
of exogenously derived dopamine. Such oscillations might allow
concomitant manifestations of severe Parkinsonism and bipha-
sic dyskinesias. This model needs further experimental valida-
tion. It also raises many questions that could be tested in future
studies:
(1) Does DBS of the STN influence both STN–thalamo-cortical
and STN–cerebellar transmission? Though the exact mech-
anisms by which DBS of the STN improves PD are not
fully established, the fact that effective DBS of the STN
improves cerebellar hyperactivity (138, 139) suggests that it
may influence both the STN–GPi and the STN–cerebellar pro-
jections. Extracellular recordings in MPTP-intoxicated pri-
mates have shown that during DBS of the STN, significant
change occurs in the pattern of neuronal activity in areas
of the motor thalamus receiving both pallidal and cerebellar
projections (140).
(2) The dose of administered levodopa has to be reduced after
immediately after DBS of the STN to reduce dyskinesia. Does
this indicate that DBS of the STN by itself cannot normalize
the aberrant plasticity within M1 caused by dopamine surges,
which would be necessary to alleviate dyskinesia? Preliminary
data showing that sensorimotor cortex plasticity improves
only after long-term synergistic combination of DBS with
reduced doses of levodopa, but not after DBS alone (141). That
long-term stimulation is required for restoring sensory affer-
ent inhibition of M1(142) indicates that cerebellar control
of sensory processing may also normalize only after chronic
stimulation of STN.
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(3) Does selective DBS of the ventral GPi but not of the dorsal
GPi or STN simultaneously inhibit the propagation of pro-
dyskinetic signals through both cortico-striatal synapses and
cerebello-striatal synapses (relayed through CM/PF thalamic
nuclei) on D1-bearing MSNs? It is already known that GPi
has functional somatotopy (143) and that ventral GPi stimu-
lation has anti-dyskinetic effects while dorsal GPi stimulation
improves akinesia and induces dyskinesias (144). In primates,
tightly connected functional circuits have been described
between basal ganglia and the CM/PF, with a sensorimotor
circuit linking the post-commissural putamen, the centro-
lateral part of the caudal GPi, and the medial two-thirds of
the CM nucleus (145). The fact that CM/PF is a target for
both pallidal and cerebellar inputs (39) might then explain
why DBS of CM/PF is useful for controlling tremor that is
resistant to DBS of the STN and also LID that are only par-
tially responsive to DBS of GPi. However, DBS alone of the
CM/PF does not change global UPDRS as strongly as DBS of
the STN or GPi (146).
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